Review studies that examined the efficacy and safety of Xultophy® 100/3.6, a combination of insulin degludec and liraglutide. The links below will take you to the abstracts of these clinical trials on PubMed.gov, the website of the US National Library of Medicine and National Institutes of Health.
Xultophy® 100/3.6 clinical studies
A 26-week, randomized, open-label trial in adult patients with type 2 diabetes inadequately controlled on insulin glargine U-100 (20-50 units) + metformin (n=557).1,2
Lingvay I, Manghi FP, García-Hernández P, et al; for the DUAL V Investigators. JAMA. 2016;315(9):898-907.
A 26-week, randomized, double-blind trial in adult patients with type 2 diabetes inadequately controlled on basal insulin (20-40 units) and metformin ± sulfonylurea or glinides.1,3
Buse JB, Vilsbøll T, Thurman J, et al; on behalf of the NN9068-3912 (DUAL-II) Trial Investigators. Diabetes Care. 2014;37(11):2926-2933.
A 26-week, randomized, open-label trial in adult patients with type 2 diabetes inadequately controlled on metformin ± pioglitazone ± sulfonylurea (n=348).1,4
Linjawi S, Bode BW, Chaykin LB, et al. Diabetes Ther. 2017;8:101-114.